BIOFRONTERA INC (BFRI)

US09077D2099 - Common Stock

1.01  +0.03 (+3.22%)

After market: 1.08 +0.07 (+6.93%)

Fundamental Rating

3

BFRI gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. While BFRI seems to be doing ok healthwise, there are quite some concerns on its profitability. BFRI is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

BFRI had negative earnings in the past year.
BFRI had a negative operating cash flow in the past year.
BFRI had negative earnings in each of the past 5 years.
BFRI had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

BFRI has a worse Return On Assets (-69.33%) than 71.58% of its industry peers.
The Return On Equity of BFRI (-232.13%) is worse than 72.63% of its industry peers.
Industry RankSector Rank
ROA -69.33%
ROE -232.13%
ROIC N/A
ROA(3y)-48.06%
ROA(5y)-45.58%
ROE(3y)-251.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 47.11%, BFRI is in the better half of the industry, outperforming 60.53% of the companies in the same industry.
In the last couple of years the Gross Margin of BFRI has declined.
The Profit Margin and Operating Margin are not available for BFRI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.11%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.02%
GM growth 5YN/A

More info and screens

4

2. Health

2.1 Basic Checks

BFRI does not have a ROIC to compare to the WACC, probably because it is not profitable.
BFRI has more shares outstanding than it did 1 year ago.
The debt/assets ratio for BFRI is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -9.57, we must say that BFRI is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -9.57, BFRI is doing worse than 74.21% of the companies in the same industry.
There is no outstanding debt for BFRI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.57
ROIC/WACCN/A
WACC9.69%

2.3 Liquidity

BFRI has a Current Ratio of 1.53. This is a normal value and indicates that BFRI is financially healthy and should not expect problems in meeting its short term obligations.
BFRI's Current ratio of 1.53 is on the low side compared to the rest of the industry. BFRI is outperformed by 71.58% of its industry peers.
BFRI has a Quick Ratio of 1.53. This is a bad value and indicates that BFRI is not financially healthy enough and could expect problems in meeting its short term obligations.
BFRI's Quick ratio of 0.94 is on the low side compared to the rest of the industry. BFRI is outperformed by 82.11% of its industry peers.
Industry RankSector Rank
Current Ratio 1.53
Quick Ratio 0.94

More info and screens

6

3. Growth

3.1 Past

BFRI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.83%, which is quite impressive.
BFRI shows a small growth in Revenue. In the last year, the Revenue has grown by 5.17%.
The Revenue has been growing by 21.81% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)71.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.88%
Revenue 1Y (TTM)5.17%
Revenue growth 3Y21.81%
Revenue growth 5YN/A
Sales Q2Q%1.3%

3.2 Future

The Earnings Per Share is expected to grow by 26.03% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 22.63% on average over the next years. This is a very strong growth
EPS Next Y83.94%
EPS Next 2Y39.82%
EPS Next 3Y26.03%
EPS Next 5YN/A
Revenue Next Year12.29%
Revenue Next 2Y15.94%
Revenue Next 3Y19.54%
Revenue Next 5Y22.63%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BFRI. In the last year negative earnings were reported.
Also next year BFRI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

BFRI's earnings are expected to grow with 26.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.82%
EPS Next 3Y26.03%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BFRI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOFRONTERA INC

NASDAQ:BFRI (12/23/2024, 7:19:59 PM)

After market: 1.08 +0.07 (+6.93%)

1.01

+0.03 (+3.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst Owners28.97%
Inst Owner Change-8.25%
Ins Owners15.67%
Ins Owner Change0%
Market Cap7.83M
Analysts82.5
Price Target11.73 (1061.39%)
Short Float %11.64%
Short Ratio0.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)39.28%
Min EPS beat(2)-15.06%
Max EPS beat(2)93.63%
EPS beat(4)1
Avg EPS beat(4)-27.76%
Min EPS beat(4)-141.33%
Max EPS beat(4)93.63%
EPS beat(8)1
Avg EPS beat(8)-31.32%
EPS beat(12)4
Avg EPS beat(12)-7.85%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-9.03%
Min Revenue beat(2)-11.71%
Max Revenue beat(2)-6.36%
Revenue beat(4)0
Avg Revenue beat(4)-14.11%
Min Revenue beat(4)-28.55%
Max Revenue beat(4)-6.36%
Revenue beat(8)1
Avg Revenue beat(8)-8.84%
Revenue beat(12)1
Avg Revenue beat(12)-6.85%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)66.67%
EPS NQ rev (3m)-110.2%
EPS NY rev (1m)5.6%
EPS NY rev (3m)5.6%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.3%
Revenue NY rev (1m)-1.19%
Revenue NY rev (3m)-1.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.22
P/FCF N/A
P/OCF N/A
P/B 1.42
P/tB 1.43
EV/EBITDA N/A
EPS(TTM)-5.71
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-2.34
FCFYN/A
OCF(TTM)-2.34
OCFYN/A
SpS4.56
BVpS0.71
TBVpS0.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -69.33%
ROE -232.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.11%
FCFM N/A
ROA(3y)-48.06%
ROA(5y)-45.58%
ROE(3y)-251.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.02%
GM growth 5YN/A
F-Score4
Asset Turnover1.91
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.57%
Cap/Sales 0.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.53
Quick Ratio 0.94
Altman-Z -9.57
F-Score4
WACC9.69%
ROIC/WACCN/A
Cap/Depr(3y)3.51%
Cap/Depr(5y)18.47%
Cap/Sales(3y)0.07%
Cap/Sales(5y)0.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.88%
EPS Next Y83.94%
EPS Next 2Y39.82%
EPS Next 3Y26.03%
EPS Next 5YN/A
Revenue 1Y (TTM)5.17%
Revenue growth 3Y21.81%
Revenue growth 5YN/A
Sales Q2Q%1.3%
Revenue Next Year12.29%
Revenue Next 2Y15.94%
Revenue Next 3Y19.54%
Revenue Next 5Y22.63%
EBIT growth 1Y16.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.35%
OCF growth 3YN/A
OCF growth 5YN/A